Roquinimex

N/A

Report date: 2022/01/14 13:23:58

NME

Base Information

Drug NameRoquinimex

Drug Alias Name罗喹美克RoquinimexumLinomidePNU-212616LS-2616 +[6]

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionImmunomodulatorsAngiogenesis inhibitors

TargetsNot applicable

Therapy Area/IndicationsLeukemia, Myeloid, AcuteLeukemia

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 3 Clinical)

Highest Status in ChinaN/A

Originator CompaniesPfizer Inc

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesPfizer Inc

Active IndicationsN/A

Inactive IndicationsLeukemia, Myeloid, AcuteLeukemia

ATC CodeL03AX02